385 related articles for article (PubMed ID: 31300567)
1. High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception.
Panchal BD; Cash R; Moreno C; Vrontos E; Bourne C; Palmer S; Simpson A; Panchal AR
J Am Board Fam Med; 2019; 32(4):474-480. PubMed ID: 31300567
[TBL] [Abstract][Full Text] [Related]
2. Counseling about medication-induced birth defects with clinical decision support in primary care.
Schwarz EB; Parisi SM; Handler SM; Koren G; Shevchik G; Fischer GS
J Womens Health (Larchmt); 2013 Oct; 22(10):817-24. PubMed ID: 23930947
[TBL] [Abstract][Full Text] [Related]
3. Prescription of teratogenic medications in United States ambulatory practices.
Schwarz EB; Maselli J; Norton M; Gonzales R
Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
[TBL] [Abstract][Full Text] [Related]
4. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.
Schwarz EB; Postlethwaite DA; Hung YY; Armstrong MA
Ann Intern Med; 2007 Sep; 147(6):370-6. PubMed ID: 17876020
[TBL] [Abstract][Full Text] [Related]
5. Provision of potentially teratogenic medications to female veterans of childbearing age.
Schwarz EB; Longo LS; Zhao X; Stone RA; Cunningham F; Good CB
Med Care; 2010 Sep; 48(9):834-42. PubMed ID: 20706159
[TBL] [Abstract][Full Text] [Related]
6. Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.
Eisenberg DL; Stika C; Desai A; Baker D; Yost KJ
J Gen Intern Med; 2010 Apr; 25(4):291-7. PubMed ID: 20087677
[TBL] [Abstract][Full Text] [Related]
7. Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study.
DiPietro Mager N; Mills C; Snelling A
Birth; 2018 Mar; 45(1):50-54. PubMed ID: 29052257
[TBL] [Abstract][Full Text] [Related]
8. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy.
Bhakta J; Bainbridge J; Borgelt L
Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786
[TBL] [Abstract][Full Text] [Related]
9. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009.
van Gelder MM; Bos JH; Roeleveld N; de Jong-van den Berg LT
Hum Reprod; 2014 Jan; 29(1):161-7. PubMed ID: 24105826
[TBL] [Abstract][Full Text] [Related]
10. Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications.
Stancil SL; Miller M; Briggs H; Lynch D; Goggin K; Kearns G
Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26676050
[TBL] [Abstract][Full Text] [Related]
11. Promoting safe prescribing in primary care with a contraceptive vital sign: a cluster-randomized controlled trial.
Schwarz EB; Parisi SM; Williams SL; Shevchik GJ; Hess R
Ann Fam Med; 2012; 10(6):516-22. PubMed ID: 23149528
[TBL] [Abstract][Full Text] [Related]
12. Pediatric Subspecialists' Practices and Attitudes Regarding Sexual and Reproductive Healthcare for Adolescent and Young Adult Women Prescribed Teratogenic Medications.
Kirkpatrick L; Michel HK; Close A; Collins A; Miller E; Kazmerski TM
J Pediatr; 2021 Jun; 233():227-232.e2. PubMed ID: 33545192
[TBL] [Abstract][Full Text] [Related]
13. An Innovative Framework to Improve Teratogenic Medication Risk Counseling.
Shroff S; McNeil M; Borrero S
J Midwifery Womens Health; 2017 May; 62(3):353-357. PubMed ID: 28485536
[TBL] [Abstract][Full Text] [Related]
14. Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.
Schwarz EB; Parisi SM; Handler SM; Koren G; Cohen ED; Shevchik GJ; Fischer GS
J Gen Intern Med; 2012 Jul; 27(7):831-8. PubMed ID: 22297687
[TBL] [Abstract][Full Text] [Related]
15. Documentation of contraceptive counseling in female veterans of reproductive age.
Schexnayder CD; King S; Emelogu O
Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S71-S77. PubMed ID: 32706019
[TBL] [Abstract][Full Text] [Related]
16. Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.
Gaudio M; Konstantara E; Joy M; van Vlymen J; de Lusignan S
BMC Pregnancy Childbirth; 2022 Jan; 22(1):73. PubMed ID: 35086478
[TBL] [Abstract][Full Text] [Related]
17. A teachable moment for providers and patients alike: contraceptive counseling when prescribing medications with teratogenic potential.
Gottlieb AS
J Womens Health (Larchmt); 2013 Oct; 22(10):795-6. PubMed ID: 24044697
[No Abstract] [Full Text] [Related]
18. Adherence to oral contraception in women on Category X medications.
Steinkellner A; Chen W; Denison SE
Am J Med; 2010 Oct; 123(10):929-934.e1. PubMed ID: 20920695
[TBL] [Abstract][Full Text] [Related]
19. Underuse of pregnancy testing for women prescribed teratogenic medications in the emergency department.
Goyal MK; Hersh AL; Badolato G; Luan X; Trent M; Zaoutis T; Chamberlain JM
Acad Emerg Med; 2015 Feb; 22(2):192-6. PubMed ID: 25639672
[TBL] [Abstract][Full Text] [Related]
20. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015.
Engeland A; Bjørge T; Klungsøyr K; Hjellvik V; Skurtveit S; Furu K
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):995-1004. PubMed ID: 29920833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
